Novo Nordisk’s share plunges 19.5% post release of weight loss drug CagriSema’s trial results
4 days, 20 hours ago

Novo Nordisk’s share plunges 19.5% post release of weight loss drug CagriSema’s trial results

Live Mint  

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday, adding the results were 25 percent they had expected. The new findings from the drug candidate deals a blow to the Danish drugmaker's ambitions for a successor to its popular Wegovy more powerful than Eli Lilly's Zepbound. Following the Danish drugmaker's results announcement, Novo's share price fell by 19.5 per cent on Friday to its lowest since August 2023. About CagriSema: CagriSema is a weekly injection by Novo Nordisk that combines semaglutide—the active ingredient in Wegovy that mimics the gut hormone GLP-1—with a separate molecule called cagrilintide, which mimics the pancreatic hormone amylin.

Drug Novo Nordisk Wegovy Novo Cagrisema  novo  post  loss  weight  wegovy  obesity  patients  nordisks  trial  drug  plunges  data  cagrisema  results  share  release

History of this topic

Eli Lilly new trial is all about the battle to be best weight-loss drug zepbound and wegovy
2 weeks, 6 days ago

Eli Lilly new trial is all about the battle to be best weight-loss drug zepbound and wegovy

India Today  

In a study trial, pharmaceutical giant Eli Lilly's weight-loss drug Zepbound showed better results than another pharmaceutical company, Novo Nordisk's weight-loss drug Wegovy. The trial, called SURMOUNT-5, compared Zepbound to Wegovy, which is a mono GLP-1 receptor agonist in adults living with obesity without diabetes. The results showed Zepbound delivering a remarkable 47% greater relative weight loss compared to Wegovy, …

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says
2 weeks, 6 days ago

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

Eli Lilly’s Zepbound beats Novo Nordisk’s Wegovy in first head-to-head study
2 weeks, 6 days ago

Eli Lilly’s Zepbound beats Novo Nordisk’s Wegovy in first head-to-head study

Live Mint  

In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. The details People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly- That translated into an average 50-pound loss for people who took Zepbound, while Wegovy users lost …

Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
1 month ago

Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices

Salon  

Semaglutide and tirzepatide medications have transformed weight loss, diabetes management, and overall health in recent years. According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market, where more than 180 million people live with obesity. Eli Lilly, Novo Nordisk’s direct competitor and the manufacturer of …

Weight-loss drug Wegovy launched in China
1 month, 1 week ago

Weight-loss drug Wegovy launched in China

CNN  

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity. Novo gained approval for Wegovy in China in June and will initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. Strong sales there and in the …

Obesity Pill Data Portend Competition, Hitting Drugmaker Shares
1 month, 2 weeks ago

Obesity Pill Data Portend Competition, Hitting Drugmaker Shares

Live Mint  

-- Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of drugmakers in the field. Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could be a reality soon: People who took 100-milligram doses …

Big Pharma’s obesity bonanza faces new tests
1 month, 2 weeks ago

Big Pharma’s obesity bonanza faces new tests

Live Mint  

In terms of recent stock-market frenzies, the Ozempic trade nearly tops the list, second only to speculation that artificial intelligence will soon be writing this column. Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players in the obesity-drug market. …

Eli Lilly is gaining on Novo Nordisk in the obesity race
4 months, 2 weeks ago

Eli Lilly is gaining on Novo Nordisk in the obesity race

Live Mint  

The two companies’ divergent earnings reports this week showed that Indianapolis-based Lilly is moving faster than its Denmark-headquartered counterpart in the race to win the GLP-1 war. Less than a year after approval, Eli Lilly’s weekly prescription volume of Zepbound is about where Novo was with Wegovy volume more than two years in, according to JPMorgan data. And while all …

Novo Nordisk shares sink after weight-loss drugs disappoint
4 months, 2 weeks ago

Novo Nordisk shares sink after weight-loss drugs disappoint

Daily Mail  

Shares in European pharma giant Novo Nordisk plunged on Tuesday after sales of a high-profile weight-loss drug disappointed in the second quarter. Titanic demand for the drugs and frenzied investor interest has driven Novo to become Europe's most valuable company, with its shares up by roughly 230 per cent since June 2021. The weight-loss drug market is forecast to be …

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results
5 months, 2 weeks ago

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Please …

Wegovy weight-loss drug OK'd in China
5 months, 4 weeks ago

Wegovy weight-loss drug OK'd in China

China Daily  

By AI HEPING in New York | chinadaily.com.cn | Updated: 2024-06-26 14:54 FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Danish drugmaker Novo Nordisk said Tuesday that its injectable weight-loss drug Wegovy has been approved in China, where the proportion of overweight and …

Wegovy weight-loss drug OK'd in China
5 months, 4 weeks ago

Wegovy weight-loss drug OK'd in China

China Daily  

FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Danish drugmaker Novo Nordisk said Tuesday that its injectable weight-loss drug Wegovy has been approved in China, where the proportion of overweight and obese adults reached almost 51 percent of the country's 1.4 billion people …

Wegovy: At least 25,000 people in the US are starting weight-loss drug each week, drugmaker says
7 months, 3 weeks ago

Wegovy: At least 25,000 people in the US are starting weight-loss drug each week, drugmaker says

CNN  

CNN — Drugmaker Novo Nordisk said it’s been increasing supply of its sought-after weight-loss drug Wegovy, with at least 25,000 people now starting to take the medicine each week in the United States. We’re talking about, many patients, chronic treatment.” Eli Lilly, Novo Nordisk’s biggest competitor, also said this week it expects supply to increase later this year. “While we …

GNC is struggling. It hopes Ozempic can give it a boost
7 months, 3 weeks ago

GNC is struggling. It hopes Ozempic can give it a boost

CNN  

New York CNN — GNC, the vitamin and dietary supplement chain, has been struggling for years. The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. GNC announced Monday that it was adding a dedicated section in its 2,300 US stores with vitamins, protein shakes …

Medicare can pay for obesity drugs like Wegovy in certain heart patients
9 months ago

Medicare can pay for obesity drugs like Wegovy in certain heart patients

Associated Press  

Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. Part D plans could begin covering the drug “some time this year,” said Tricia Neuman, a Medicare policy specialist at …

Medicare can pay for obesity drugs like Wegovy in certain heart patients
9 months ago

Medicare can pay for obesity drugs like Wegovy in certain heart patients

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Medicare can pay for the …

Novo Nordisk pays $25.8 million to promote its obesity drug
1 year ago

Novo Nordisk pays $25.8 million to promote its obesity drug

Live Mint  

During his address, Dr. Lee Kaplan urged fellow doctors to use their prescription pads to fight the obesity crisis, according to a report by Reuters on December 1. Dr. Kaplan, a leading U.S. weight-loss specialist, recommended turning to new weight-loss medicines like Novo Nordisk's Wegovy to reduce obesity. “We are going to have to use these medications,” he said at …

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates
1 year, 1 month ago

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates

Associated Press  

NEW YORK — Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market. It notably priced the drug at roughly a 20% discount to Novo Nordisk’s Wegovy as the companies try to entice more employers to include weight-loss drugs in their …

AstraZeneca joins obesity drug craze as it signs £1.6bn deal with Chinese medical group
1 year, 1 month ago

AstraZeneca joins obesity drug craze as it signs £1.6bn deal with Chinese medical group

Daily Mail  

AstraZeneca has entered the race to develop a weight-loss drug after striking a £1.6billion deal with a Chinese medical group. China deal: AstraZeneca boss Pascal Soriot said that the move into weight loss drugs follows 'enormous need around the world' Details emerged just hours after it was revealed that AstraZeneca is facing a multi-million-pound legal battle over claims the efficacy …

The obesity drugs waiting to hit the market
1 year, 4 months ago

The obesity drugs waiting to hit the market

The Hindu  

Novo Nordisk said a large study had shown its highly effective obesity drug Wegovy also had a clear cardiovascular benefit, boosting the Danish drugmaker’s hopes of moving beyond Wegovy’s image as a lifestyle drug. The following is a list of companies targeting the next big blockbuster opportunity: Novo Nordisk said a large study had shown its highly effective obesity drug, …

Obesity drug Wegovy reduces heart attacks and strokes risk by 20%, shows study
1 year, 4 months ago

Obesity drug Wegovy reduces heart attacks and strokes risk by 20%, shows study

Hindustan Times  

Novo Nordisk A/S shares surged to a record after the Danish company’s blockbuster obesity medicine Wegovy reduced the risk of heart attacks and strokes in a highly anticipated study, giving it another potential boost. Obesity drug Wegovy reduces heart attacks and strokes risk by 20%, shows study Patients with obesity or overweight and with a history of cardiovascular issues taking …

No more needles? A daily pill may work as well as Wegovy shots to treat obesity
1 year, 5 months ago

No more needles? A daily pill may work as well as Wegovy shots to treat obesity

Associated Press  

What if treating obesity could be as easy as popping an effective pill? “If you ask people a random question, ‘Would you rather take a pill or an injection?’ People overwhelmingly prefer a pill,” said Dr. Daniel Bessesen, chief of endocrinology at Denver Health, who treats patients with obesity but was not involved in the new research. Another 16-month study …

What is the new wonder weight loss drug?
1 year, 9 months ago

What is the new wonder weight loss drug?

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. The patient information leaflet for the drug states that …

A new class of drugs for weight loss could end obesity
1 year, 9 months ago

A new class of drugs for weight loss could end obesity

Live Mint  

How did Kim Kardashian, a reality tv star, lose enough weight to fit into a slinky dress once worn by Marilyn Monroe? Fatima Stanford, who studies obesity at Massachusetts General Hospital and Harvard Medical School, notes that attempts to lose weight through diet and exercise work for only 10-20% of the population: “For most people we don’t see a dramatic …

Novo Nordisk Statement to 60 Minutes
1 year, 11 months ago

Novo Nordisk Statement to 60 Minutes

CBS News  

Promising new weight loss medication in short supply and often not covered by insurance | 60 Minutes Prior to 60 Minutes', January 1, 2023, broadcast which featured correspondent Lesley Stahl's story on obesity, we reached out to Novo Nordisk, the maker of Wegovy and Ozempic about recent shortages of the medications. The company told 60 Minutes the following: Ozempic The …

FDA approves obesity drug that helped people cut weight 15%
3 years, 6 months ago

FDA approves obesity drug that helped people cut weight 15%

Associated Press  

Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide, for long-term weight management. “With existing drugs, you’re going to get maybe 5% to 10% weight reduction, sometimes not even that,” said …

Discover Related